Catalyst Biosciences Inc CBIO shares are trading higher by 180.26% at $1.06 after the company announced it sold its complement portfolio for $60 million.
A definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated VRTX has allowed Vertex to acquire Catalyst's portfolio of protease medicines that regulate complement, including CB 2782-PEG, for $60 million in cash.
See Also: Why Inovio Pharmaceuticals Stock Is Rising Today
Catalyst Biosciences is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals.
According to data from Benzinga Pro, Catalyst Biosciences has a 52-week high of $5.20 and a 52-week low of $3.05.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
